The Economic Times

AbbVie in advanced talks to buy cancer drugmaker revolution medicines, shares jump nearly 30%

AbbVie is in advanced talks to buy Revolution Medicines, a cancer drug company. The news pushed Revolution Medicines shares sharply higher. Investors see the deal as a growth move for AbbVies cancer business. The possible acquisition supports AbbVies plan to replace revenue lost after Humira patents expired and strengthen its future drug pipeline.